Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 17
2003 12
2004 14
2005 20
2006 19
2007 18
2008 19
2009 10
2010 11
2011 20
2012 14
2013 11
2014 21
2015 20
2016 16
2017 20
2018 25
2019 14
2020 17
2021 17
2022 10
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y; EMPA-ELDERLY Investigators. Yabe D, et al. Among authors: seino y. Diabetes Obes Metab. 2023 Dec;25(12):3538-3548. doi: 10.1111/dom.15249. Epub 2023 Aug 25. Diabetes Obes Metab. 2023. PMID: 37622398 Clinical Trial.
Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia.
Haraguchi T, Hamamoto Y, Kuwata H, Yamazaki Y, Nakatani S, Hyo T, Yamada Y, Yabe D, Seino Y. Haraguchi T, et al. Among authors: seino y. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e69-e75. doi: 10.1210/clinem/dgad483. J Clin Endocrinol Metab. 2023. PMID: 37597171
Efficacy and Safety of 6-Month High Dietary Protein Intake in Hospitalized Adults Aged 75 or Older at Nutritional Risk: An Exploratory, Randomized, Controlled Study.
Moyama S, Yamada Y, Makabe N, Fujita H, Araki A, Suzuki A, Seino Y, Shide K, Kimura K, Murotani K, Honda H, Kobayashi M, Fujita S, Yasuda K, Kuroe A, Tsukiyama K, Seino Y, Yabe D. Moyama S, et al. Among authors: seino y. Nutrients. 2023 Apr 22;15(9):2024. doi: 10.3390/nu15092024. Nutrients. 2023. PMID: 37432141 Free PMC article. Clinical Trial.
Identifying nerve to vastus medialis at adductor canal entry.
Watanabe T, Mera H, Seino Y. Watanabe T, et al. Among authors: seino y. J Anesth. 2023 Oct;37(5):813-814. doi: 10.1007/s00540-023-03213-4. Epub 2023 Jun 26. J Anesth. 2023. PMID: 37358672 No abstract available.
305 results